Parx Materials provides update on Oriental International Group partnership
First production phase of antimicrobial lyocell fibre initiated
Rotterdam, the Netherlands, 8 July 2026. Parx Materials N.V. (Euronext: MLPRX) today provides an update on the progress of its strategic partnership with Oriental International Group.
Following a preparation period, and against a backdrop of elevated and volatile raw material prices that have affected the wider textile value chain in recent months, the partners have agreed to commence the first production phase of antimicrobial lyocell fibre incorporating Parx Materials' biocide-free zinc technology.
This initial phase is expected to yield approximately 40 tonnes of antimicrobial lyocell fibre. The volume of Parx technology used in this phase was contracted and delivered under the companies' existing agreement. Accordingly, the milestone does not in itself represent additional revenue for Parx Materials in the current period. Its significance lies in the transition from qualification to active production, an important technical and commercial validation of the technology at industrial scale.
Parx Materials will provide further updates as the partnership develops.
Forward-looking statements
This announcement contains forward-looking statements that reflect the company's current expectations. Actual results may differ materially due to factors including raw material prices, market conditions and the pace of commercial adoption. Parx Materials undertakes no obligation to update these statements except as required by law.
About Parx Materials N.V.
Parx Materials N.V., headquartered in Rotterdam, the Netherlands, is a pioneer in developing physical antimicrobial technologies based on biocompatible zinc compounds. The company holds multiple patents worldwide and its technology has been successfully applied in the fields of medical devices, food packaging, textiles and consumer goods. Parx Materials' technologies have been recognised in international innovation awards and have received regulatory approval in key markets around the world.